Yazar "Ural, D." seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Comparison of outcome in systolic heart failure patients using ivabradine, digoxin or neither of them: a real life study(Wiley, 2017) Ural, D.; Mutluer, F. O.; Kaya, H.; Beton, O.; Cavusoglu, Y.; Temizhan, A.; Guvenc, T. S.; Gungor, H.; Ege, M. Refiker; Zoghi, M.; Karauzum, K.; Altay, H.; Yilmaz, M. B.Öğe Decrease in prevalence of hypertension in 15 years: a success story of a population through salt reduction initiatives(Oxford Univ Press, 2018) Kilickap, M.; Barcin, C.; Goksuluk, H.; Karaaslan, D.; Ozer, N.; Kayikcioglu, M.; Ural, D.; Yilmaz, M. B.; Abaci, A.; Tokgozoglu, L.Öğe Effect of increasing doses of rosuvastatin on lipoprotein particles and inflammatory parameters in patients with metabolic syndrome and low HDL level(Oxford Univ Press, 2011) Ural, D.; Sansoy, V.; Yigit, Z.; Esen, A. M.; Oguzhan, A.; Gurgun, C.; Kutlu, M.; Boyaci, B.; Yuksel, H.Öğe Event-Free Familial Hypercholesterolemia in The Elderly: a Retrospective Analysis of The Characteristics and Clinical Contributors(Elsevier Ireland Ltd, 2023) Ozdemir, O.; Alghothani, O.; Ural, D.; Yurtseven, E.; Gursoy, E.; Kayikcioglu, M.[No abstract available]Öğe Influence of influenza vaccination on recurrent hospitalization in patients with heart failure(Urban & Vogel, 2017) Kaya, H.; Beton, O.; Acar, G.; Temizhan, A.; Cavusoglu, Y.; Guray, U.; Zoghi, M.; Ural, D.; Ekmekci, A.; Gungor, H.; Sari, I.; Oguz, D.; Yucel, H.; Zorlu, A.; Yilmaz, M. B.The current study aimed to evaluate the influence of regular annual influenza vaccinations on cardiovascular (CV) death and heart failure-related hospitalizations (HFrH) in stable outpatients with heart failure with reduced ejection fraction. The Turkish research team-HF (TREAT-HF) is a network undertaking multicenter, observational cohort studies in HF. This study is a subgroup analysis of TREAT-HF outpatient cohorts who completed a questionnaire on influenza vaccination status and for whom follow-up data were available. A total of 656 patients with available follow-up data for CV death and HFrH including recurrent hospitalization were included in the study. Patients were classified into two groups: those who received regular influenza vaccination (40 %) and those who did not receive vaccination. During a mean follow-up of 15 +/- 6 months, 113 (18 %) patients had CV death and 471 (72 %) patients had at least one HFrH. The CV death rate was similar in both groups of patients (16 vs. 19 %, p = 0.37), whereas, HFrH and recurrent HFrH were significantly less frequently encountered in patients who received regular influenza vaccination than in those who did not receive vaccination (43 vs. 92 % and 16 vs. 66 %, p < 0.001, respectively). In a multivariate Cox proportional hazards model - in addition to a few clinical factors - vaccination status (HR = 0.30, 95 % CI = 0.17-0.51, p < 0.001) and graduation from university (HR = 0.35, 95 % CI = 0.17-0.72, p = 0.004) remained independently associated with the risk of recurrent HFrH. Regular influenza vaccination does not influence CV deaths; however, it decreases HFrH including recurrent episodes of HFrH in outpatients with heart failure with reduced ejection fraction.Öğe TEMPORAL TRENDS IN OBESITY AND STATUS OF DYSLIPIDEMIA IN TURKEY: A META-ANALYSIS OF EPIDEMIOLOGICAL STUDIES(Elsevier Ireland Ltd, 2018) Tokgozoglu, L.; Ural, D.; Kayikcioglu, M.; Kilickap, U.; Goksuluk, H.; Karaaslan, D.Öğe Trends in heart failure between 2016 and 2022 in Türkiye (TRends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages(Elsevier Ltd, 2023) Celik, A.; Ural, D.; Sahin, A.; Colluoglu, I.T.; Kanik, E.A.; Ata, N.; Arugaslan, E.Background: Data on the burden of heart failure (HF) outside western countries are limited, but available data suggest it may present differently in other countries. The aim of this study was to examine the incidence, prevalence, and survival rates of HF in Türkiye, with a specific focus on how these rates vary according to age, sex, comorbidities, and socioeconomic status (SES). Methods: We harnessed the extensive National Electronic Database of the Turkish Ministry of Health, covering Turkey's entire population from January 1, 2016, to December 31, 2022, to identify 2,722,151 cases of HF and their associated comorbidities using ICD-10 codes. Analyzing the primary endpoint of all-cause mortality, our study utilized anonymized data to examine patient demographics, comorbidities, socioeconomic status, and survival patterns, employing statistical techniques to delve into relationships and trends. The data were segmented by gender, socioeconomic status, and age, involving cross-tabulations and statistical metrics to explore connections, odds ratios, and survival rates. Findings: The estimated prevalence of HF was 2.114% in Türkiye at the end of 2022, with an annual incidence ranging between 3.00 and 6.06 per 1000 person years. Females were older than males (69.8 ± 13.9 years vs. 66.8 ± 13.9 years, respectively). The most common comorbidities were congenital heart diseases and anemia under the age of 20, and hypertension and atherosclerotic cardiovascular disease in the adult population. Only 23.6% (643,159/2,722,151) of patients were treated with any triple guideline-directed medical therapy (GDMT) and 3.6% (96,751/2,722,151) of patients were on quadruple GDMT. The survival rates for patients with HF at 1, 5, and 7 years were 83.3% (95% CI: 83.2–83.3), 61.5% (95% CI: 61.4–61.6), and 57.7% (95% CI: 57.6–57.8) among females, and 82.1% (95% CI: 82.0–82.2), 58.2% (95% CI: 58.1–58.3), and 54.2% (95% CI: 54.0–54.3) among males. Despite a tendency for an increase from the highest to the lowest SES, the prevalence of HF and mortality were paradoxically lowest in the lowest SES region. Interpretation: The prevalence, incidence, and survival rates of HF in Türkiye were comparable to western countries, despite the notable difference of HF onset occurring 8–10 years earlier in the Turkish population. Drug usage statistics indicate there is a need for effective strategies to improve treatment with GDMT. Funding: None. © 2023 The Author(s)Öğe What we learned from the analysis of first 301 patients from the Turkish Peripartum Cardiomyopathy Registry?(Oxford Univ Press, 2018) Kayikcioglu, M.; Tokgozoglu, L.; Biteker, M.; Akil, M. A.; Ertas, F.; Nalbantgil, S.; Yilmaz, E.; Yilmaz, D. C.; Askin, L.; Asarcikli, L. D.; Mutluer, F. O.; Ural, D.; Temizhan, A.
